New hope for tough cancer: experimental drug joins fight against pancreatic tumors
NCT ID NCT07255404
Summary
This study is testing whether adding an experimental drug called pumitamig (BNT327) to standard chemotherapy helps people with newly diagnosed metastatic pancreatic cancer. It will involve about 105 adults who have not yet received treatment for their advanced cancer. The main goals are to see if the combination shrinks tumors and is safe for patients.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC DUCTAL ADENOCARCINOMA (PDAC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fudan University Shanghai Cancer Center
RECRUITINGShanghai, 201318, China
Conditions
Explore the condition pages connected to this study.